Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Google DeepMind's spinoff Isomorphic Labs is set to begin human trials of a drug desinged completely by Artificial ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Eli Lilly and Company (NYSE: LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, ...

The Howard County Board of Education is suing several Big Pharma companies for allegedly inflating insulin prices, affecting ...